Few treatment options for multidrug-resistant tuberculosis (TB) and extensively drug-resistant TB call attention to the development of novel therapeutic approaches for TB. Therapeutic vaccines are promising candidates because they can induce antigen-specific cellular immune responses, which play an important role in the elimination of Mycobacterium tuberculosis (MTB). In this study, a novel lentiviral vector therapeutic vaccine for delivering MTB-specific fusion protein Ag85B-Rv3425 was constructed. Results showed that one single-injection of this recombinant lentivirus vaccine could trigger antigen-specific Th1-type immune responses in mice. More importantly, mice with acute infection benefited a lot from a single-dose administration of this vaccine by markedly reduced MTB burdens in lungs and spleens as well as attenuated lesions in lungs compared with untreated mice. These results displayed good prospects of this novel vaccine for the immunotherapy of TB.
[1]Chinese Acad Sci, Inst Pasteur Shanghai, Key Lab Mol Virol & Immunol, Unit AntiTB Immun, Shanghai 200031, Peoples R China.
[2]Fudan Univ, Shanghai Med Coll, Dept Med Microbiol & Parasitol, Shanghai 200032, Peoples R China.
[3]Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.
[4]Shanghai Jiao Tong Univ, Shanghai Childrens Hosp, Dept Neonatol, Shanghai 200040, Peoples R China.
(8.0+极速模式)